A Phase I/II Study of 177Lu-HH1 (Betalutin) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma.

Trial Profile

A Phase I/II Study of 177Lu-HH1 (Betalutin) Radioimmunotherapy for Treatment of Relapsed Non-Hodgkin Lymphoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Lutetium-(177lu) lilotomab satetraxetan (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man
  • Acronyms LYMRIT37-01
  • Sponsors Nordic Nanovector
  • Most Recent Events

    • 25 Jun 2017 Results of a pharmacokinetic sub-study (n=22), presented at the 22nd Congress of the European Haematology Association.
    • 15 Jun 2017 According to a Nordic Nanovector media release, data from this trial presented at the International Conference on Malignant Lymphoma (ICML).
    • 14 Jun 2017 Results (data cut-off date of 6 May 2017) from this trial published in a Nordic Nanovector Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top